about
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitusBiosimilar insulins: guidance for data interpretation by clinicians and usersBiosimilar Insulins: Basic ConsiderationsPharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase.Evaluation of a novel continuous glucose measurement device in patients with diabetes mellitus across the glycemic range.Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin.Biosimilar insulins: how similar is similar?Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjectsComparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase.Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetesA novel insulin formulation with a more rapid onset of action.Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males.Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes.Capillary and venous blood glucose concentrations measured during intravenous insulin and glucose infusion: a comparison of steady and dynamic states.Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes.Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus.Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups.Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin.Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes.Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers.Glycemic exposure is affected favorably by inhaled human insulin (Exubera) as compared with subcutaneous insulin glargine (Lantus) in patients with type 2 diabetes.Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action.Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes.Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metforminSafety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus.Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction.Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.Continuous glucose monitoring using a novel glucose/galactose binding protein: results of a 12-hour feasibility study with the becton dickinson glucose/galactose binding protein sensor.Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetesalpha-Lipoic acid in NIDDM patients with cardiac autonomic neuropathyShort-term metabolic effects of prednisone administration in healthy subjectsDeveloping new drugs for diabetes and cardiometabolic disorders: a changing paradigmAlbiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitusTargeting hyperglycaemia with anti-obesity drugs: time for a paradigm shift?Anti-Obesity Pharmacotherapy: The Intercontinental Regulatory Divide
P50
Q21195757-E8553335-C6FE-4DDA-8A72-9AB2C4CF02AAQ26992066-CB8B31DD-7808-407A-AC11-966CD973B7E1Q28646059-5850C970-FB9B-4059-80F2-812F4A6C0E90Q34105064-1DE0D9C8-270A-444E-8084-7BFB3C9EF65CQ34583346-9BE32747-AAFF-43F9-A302-126F22CA91C9Q35336859-9955E95F-FBC9-4D8D-BE6A-AFDF46EA67D5Q35337607-4B220287-23A0-450C-BB31-2D3231DC03C2Q35337749-9F74D6EA-9D14-4D97-9B16-AEF227BD6319Q35563634-74FF4485-2882-4FCF-B505-1B426E163C7DQ36560273-E6EF1E74-BDCD-414B-8F63-05AB457AABC3Q37193454-16F046E3-59B6-43FD-8D40-5691D7154729Q41816866-AA79A43C-DF9A-49E8-B413-D030C3EE06A3Q42654819-18B0B7E5-46FB-458C-9A01-9E37B2DFC896Q43052215-332AF350-8534-4808-8281-66352F870330Q43263281-6ABDB040-97FA-42D1-A56D-BC3910673CAFQ43275328-98BD80AB-4058-4EB0-ADD9-2CAAFB795908Q44558937-E2CA3809-31B1-479E-839B-D5E94C3A9EB5Q44868418-380DFBE9-79DA-47C2-93C5-B8B5F0418DA7Q45024401-A512B3FA-3F02-4694-A5B9-E30FBF1D2A68Q45242377-41D3562A-50FF-413F-8CD9-EEE67C96F86CQ45942686-AB41CC89-5F50-4B45-A16E-B9EA4EAC716EQ45963931-06BE1A51-0AEB-42A0-839D-8F06981725F4Q46102214-FED1BCE2-B668-4889-9615-AE8076A0CCC3Q46358093-CDC38DF2-8AD2-4DCF-B3B9-E6FDB8164CA4Q47173372-CCEA722A-9DCC-4A72-A938-BDC33239F622Q47317632-2E75D8D7-F354-4908-8553-8D69944B065DQ51321214-CA81DB44-8F2C-4D2A-8E83-ECDABB0660D6Q51354362-D3F2A095-207F-4FE9-AAB9-45B05DBD39F6Q51362851-1C5BAD89-8FDE-47B1-9430-5160C05CE30DQ51629947-1CE2D763-CF5C-4EB3-AC1C-DA4E40EF3029Q53436307-0B7885E7-7349-4DDC-B1FA-8D8D295C1698Q53439322-A2803F88-F142-43CA-A356-D961BB5AAA27Q57222384-BD1E76D9-F3CE-44A8-9C22-19A5E615583CQ73957216-B099443B-7F11-49EC-879E-84F147E13869Q84256394-81EBB2A2-B9D4-4C6E-BB99-F310B28F70E4Q84893842-9F6E58E5-D082-4486-809B-B60620E7BF73Q85645198-11A71EEC-6411-4EDB-B1F7-94DE84D5E6E7Q86447201-319B1042-595C-407D-927E-BDF9E8D49C1FQ87288143-9AA9A69F-8C09-484F-B5DB-47A7FB50B7C4
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marcus Hompesch
@ast
Marcus Hompesch
@en
Marcus Hompesch
@es
Marcus Hompesch
@nl
Marcus Hompesch
@sl
type
label
Marcus Hompesch
@ast
Marcus Hompesch
@en
Marcus Hompesch
@es
Marcus Hompesch
@nl
Marcus Hompesch
@sl
prefLabel
Marcus Hompesch
@ast
Marcus Hompesch
@en
Marcus Hompesch
@es
Marcus Hompesch
@nl
Marcus Hompesch
@sl
P106
P21
P31
P496
0000-0001-5867-2131